A new experimental drug called ribupatide reduced body weight by 4.3 to 7.7 kilograms (6.7% to 9.6%) over four weeks in a Phase 1 trial of 90 healthy adults, compared to 1.2 kilograms in the placebo group. According to Gram Research analysis, the drug was safe and well-tolerated with no serious side effects, and it also lowered fasting blood sugar levels in a dose-dependent manner. However, this is very early-stage research in healthy people, not patients with diabetes or obesity, so much more testing is needed before ribupatide could become available as a treatment.
Researchers tested a new experimental drug called ribupatide (HRS9531) that works on two different body systems to help control blood sugar and weight. In early human trials with 90 healthy Chinese participants, the drug was safe and well-tolerated, with no serious side effects. People taking ribupatide lost between 4.3 to 7.7 kilograms over four weeks, compared to just 1.2 kilograms in the placebo group. According to Gram Research analysis, these promising first-in-human results suggest ribupatide could become a new treatment option for type 2 diabetes and obesity, though more testing is needed.
Key Statistics
A Phase 1 trial of 90 healthy Chinese participants found that ribupatide produced weight loss ranging from 4.3 to 7.7 kilograms (6.7% to 9.6% of body weight) over four weeks, compared to 1.2 kilograms (1.4%) in the placebo group.
In a 2026 first-in-human study of the dual GLP-1/GIP receptor agonist ribupatide, 96.7% of 90 participants completed the trial with no serious adverse events or deaths reported across all dose levels.
Ribupatide demonstrated a half-life of 7 to 8 days in humans, supporting once-weekly subcutaneous administration for potential type 2 diabetes and obesity treatment.
Fasting plasma glucose decreased in a dose-dependent manner after both single and multiple doses of ribupatide in the Phase 1 trial, with the highest dose producing the greatest blood sugar reduction.
The Quick Take
- What they studied: Whether a new experimental drug called ribupatide is safe and effective at lowering blood sugar and reducing weight in humans.
- Who participated: 90 healthy Chinese adults were randomly assigned to receive either ribupatide at different doses or a placebo injection once weekly for four weeks. Most participants (96.7%) completed the entire study.
- Key finding: After four weeks of weekly injections, people taking ribupatide lost 4.3 to 7.7 kilograms (6.7% to 9.6% of body weight), while the placebo group lost only 1.2 kilograms (1.4%). Blood sugar levels also dropped in a dose-dependent manner.
- What it means for you: This is very early-stage research in healthy people, not patients with diabetes or obesity. While results are encouraging, ribupatide is still experimental and years away from potential approval. Do not expect this drug to be available soon, and always consult your doctor about current treatment options.
The Research Details
This was a Phase 1 clinical trial, which is the first step in testing new drugs in humans. The researchers started by studying ribupatide in laboratory cells, then in animals (rats and obese mice), before finally testing it in 90 healthy human volunteers. The human study had two parts: first, participants received single doses ranging from very small (0.1 mg) to larger amounts (8.1 mg) to see how the body handled the drug. Second, a different group received weekly injections of the same drug for four weeks to understand how it worked with repeated dosing. Participants were randomly assigned to receive either ribupatide or a placebo (fake injection), and researchers tracked safety, side effects, blood sugar levels, and weight changes throughout the study.
Phase 1 trials are crucial because they establish whether a new drug is safe enough to test further in patients who actually have the disease. By studying the drug’s behavior in the body (pharmacokinetics) and its effects on blood sugar and weight (pharmacodynamics), researchers can determine the right doses to use in future studies. The animal studies provided early evidence that ribupatide could work, making the human trial justified and scientifically sound.
This study has several strengths: it was randomized (reducing bias), included both preclinical and clinical data, had a high completion rate (96.7%), and was published in a peer-reviewed journal. However, participants were all healthy, not people with diabetes or obesity, so results may differ in actual patients. The sample size of 90 is appropriate for Phase 1 but relatively small. The study was conducted in China with Chinese participants, so results may vary in other populations.
What the Results Show
Ribupatide was safe and well-tolerated at all tested doses. No serious side effects or deaths occurred during the study. All reported side effects were mild to moderate in severity, meaning they were not dangerous or debilitating. The drug stayed in the body for 7 to 8 days after injection, which supports giving it once weekly rather than more frequently. Fasting blood sugar levels decreased in a dose-dependent manner, meaning higher doses produced greater reductions in blood sugar. This is important because it shows the drug works as intended and that researchers can control its effects by adjusting the dose.
Weight loss was the most impressive finding. After four weekly injections, participants receiving the highest dose of ribupatide lost an average of 7.7 kilograms (9.6% of their body weight), compared to only 1.2 kilograms (1.4%) in the placebo group. Even participants receiving lower doses lost meaningful amounts of weight, ranging from 4.3 to 6.9 kilograms. This weight loss occurred alongside reduced food intake, suggesting the drug affects appetite control. The dose-dependent relationship between ribupatide amount and weight loss suggests researchers can fine-tune the drug’s effects.
Ribupatide belongs to a class of drugs called GLP-1 and GIP receptor agonists. Similar drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro) have already shown impressive weight loss and blood sugar control in patients. This study suggests ribupatide may work similarly or potentially better, though direct comparisons cannot be made from this early-stage research. The once-weekly dosing is consistent with other drugs in this class, making it convenient for patients.
The biggest limitation is that all participants were healthy, not people with diabetes or obesity. Results in actual patients may differ significantly. The study was short (four weeks), so we do not know about long-term effects or safety. Only 90 people participated, which is small for understanding rare side effects. All participants were Chinese, so results may not apply equally to other ethnic groups. This was Phase 1, meaning much more testing is needed before the drug could be approved for use.
The Bottom Line
This research is too early-stage to make recommendations for patients. Ribupatide is experimental and not available outside clinical trials. If you have type 2 diabetes or obesity, continue working with your doctor on current approved treatments. Monitor clinical trial announcements if you are interested in participating in future ribupatide studies. Confidence level: This is preliminary data that requires confirmation in larger, longer studies in actual patients.
Researchers and pharmaceutical companies developing new diabetes and obesity treatments should pay attention to these results. People with type 2 diabetes or obesity may eventually benefit if ribupatide advances through clinical trials and gains approval, but that is years away. Healthcare providers should stay informed about this drug class as it develops. People should not seek out ribupatide or expect it to be available soon.
Ribupatide is currently in Phase 1 testing. Typically, a new drug requires 5 to 10 years of additional testing before potential approval. Phase 2 trials (testing in patients with the disease) would come next, followed by Phase 3 trials (larger, longer studies), regulatory review, and potential approval. Even if everything goes smoothly, ribupatide is unlikely to be available to the general public before 2030 at the earliest.
Frequently Asked Questions
Is ribupatide available to buy or use as a treatment right now?
No, ribupatide is still experimental and only available in clinical trials. It is in Phase 1 testing, meaning it has only been tested in healthy volunteers. Years of additional testing in patients with diabetes and obesity are required before potential approval by regulatory agencies.
How does ribupatide compare to other weight loss drugs like Ozempic or Zepbound?
Ribupatide works similarly to existing drugs like semaglutide and tirzepatide by activating GLP-1 and GIP receptors. Early results suggest comparable or potentially better effects, but direct comparisons cannot be made from this early-stage research. More studies are needed to determine how ribupatide stacks up against approved medications.
What were the side effects of ribupatide in the study?
All reported side effects were mild to moderate in severity, with no serious adverse events or deaths. The study did not specify which side effects occurred, but similar drugs in this class commonly cause nausea, vomiting, and gastrointestinal symptoms, especially when starting treatment.
Can I participate in a ribupatide clinical trial?
Possibly, but only if you meet specific eligibility criteria for ongoing trials. Check ClinicalTrials.gov (identifier NCT05152277) or contact the drug manufacturer for information about current and upcoming ribupatide studies. Phase 2 trials in patients with diabetes and obesity would be the next step.
Why test a new drug in healthy people instead of people with diabetes?
Phase 1 trials in healthy volunteers establish basic safety and how the body processes the drug before testing in patients. This protects people with the disease from unknown risks. Once safety is confirmed, Phase 2 trials test effectiveness in actual patients with the condition.
Want to Apply This Research?
- Users interested in weight loss and blood sugar management can track weekly weight measurements and fasting blood glucose levels using the app’s health logging feature. This creates a baseline for comparing against future treatments and helps identify patterns in response to lifestyle changes.
- Set weekly reminders to weigh yourself and log fasting blood sugar if you have a home glucose monitor. Use the app to track meals and activity levels, which helps identify factors affecting your weight and blood sugar independent of medication.
- Create a long-term health dashboard showing weight trends, average blood glucose readings, and medication adherence. Share monthly summaries with your healthcare provider to track progress on current treatments and inform discussions about future options as they become available.
This article discusses early-stage research on an experimental drug not yet approved for human use outside clinical trials. The findings are preliminary and based on a small study in healthy volunteers, not patients with diabetes or obesity. Results may differ significantly when tested in actual patients. Do not attempt to obtain or use ribupatide outside of authorized clinical trials. Always consult with your healthcare provider before making any changes to diabetes or weight management treatment. This information is for educational purposes only and should not be considered medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.